Name:L-lysine aescinate (L-Lysine Aescinat)
Indications for use:
Post-traumatic, intra- and postoperative swelling of any localization: severe swelling of the brain and spinal cord, including subarachnoid and intracranial hematomas and displacement of the midline structures of the brain and edema-swelling syndrome; swelling of soft tissues involving the musculoskeletal system, accompanied by local disorders of their blood supply and pain syndrome; edematous and pain syndromes of the spine, trunk, limbs; severe disorders of venous circulation of the lower extremities in acute thrombophlebitis, accompanied by edematous-inflammatory syndrome.
Pharmacological action:
Pharmacodynamics.
The drug has anti-inflammatory, anti-edematous and analgesic effects. Escin reduces the activity of lysosomal hydrolases, which prevents the breakdown of mucopolysaccharides in the walls of capillaries and in the connective tissue that surrounds them, and thus normalizes increased vascular tissue permeability and has anti-exudative (anti-edematous), anti-inflammatory and analgesic effects. The drug increases vascular tone, has moderate immunocorrective and hypoglycemic effects.
L-Lysine Aescinat (L-lysine aescinate) method of administration and doses:
The daily dose of the product for adults is 5-10 ml. 5-10 ml of the product is diluted in 15-50 ml of sodium chloride solution for injection 0.9% and administered only intravenously (intra-arterial administration is not allowed). In conditions that threaten the life of the patient (acute craniocerebral injury, intra- and postoperative swelling of the brain and spinal cord with symptoms of edema-swelling, swelling of large sizes due to common injuries of soft tissues and the musculoskeletal system), the daily dose is increased to 10 ml twice a day.
The maximum daily dose for adults is 25 ml. The duration of the product is 2-8 days, depending on the effectiveness of therapy. In children, a single dose is administered at the rate of: 1-5 years – 0.22 mg of L-lysine aescinate per kg of body weight; 5-10 years – 0.18 mg of L-lysine aescinate per kg of body weight; 10 years and older – 0.15 mg of L-lysine aescinate per kg of body weight; over 10 years old – 0.12 mg of L-lysine aescinate aescin per kg of body weight. The drug is administered 2 times a day. The duration of the course is from 2 to 8 days, depending on the condition of the patient and the effectiveness of therapy.
L-Lysine Aescinat (L-lysine aescinate) contraindications:
The drug is contraindicated in patients with severe renal impairment, as well as in persons with increased individual susceptibility to the product components. Children under 1 year old.
FEATURES OF APPLICATION.
In some patients with hepatocholecystitis, when prescribing the drug, a short-term increase in transaminase activity is possible, which does not pose a threat to the sick and does not require the drug to be discontinued. There is no experience of use in pregnant women and in women during lactation.
INTERACTION WITH OTHER DRUGS.
In the treatment of L-lysine with aescinat, it is possible to prescribe other drugs for appropriate indications (anti-inflammatory, analgesics, antimicrobials). The drug should not be used simultaneously with aminoglycosides due to the possibility of increasing their nephrotoxicity. If it is necessary to simultaneously prescribe L-lysine aescinate and anticoagulants, the doses subsequently need to be reduced (control of the prothrombin index). Plasma protein binding of escin is impaired by the concomitant use of cephalosporin antibiotics, which may increase the concentration of free escin in the blood with the risk of developing side effects in the aftermath.
L-Lysine Aescinat (L-lysine aescinat) side effects:
With individual sensitivity to escin, individual patients may experience allergic reactions in the form of a skin rash, urticaria, and angioedema.
Release form:
Solution for injections.
Pack: 10 ampoules of 5 ml in a box.
L-Lysine Aescinat (L-lysine aescinate) composition:
Clear, colorless solution;
L-Lysine Aescinat (L-lysine aescinate) composition: 1 ml of solution contains L-lysine aescinate (in terms of 100% substance) 0.001 g; excipients: ethyl alcohol 96%, propylene glycol, water for injection.
Storage conditions:
Keep out of the reach of children, protected from light at a temperature of +15°С to +25°С.
Shelf life – 2 years.
Leave conditions – according to the recipe.
Additionally:
Producer: JSC “Galicpharm”.
Attention!
Before using the medication“L-Lysine Aescinat (L-lysine aescinat)” should be consulted with a doctor.
The instructions are provided solely for familiarization with “L-Lysine Aescinat (L-lysine aescinat) “.